Immune monitoring in patients with NSCLC receiving immune checkpoint inhibitors

Immune monitoring in patients with NSCLC receiving immune checkpoint inhibitors - Immune monitoring in patients with NSCLC receiving immune checkpoint inhibitors

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026140

Enrollment

Registered

2017-02-15

Start date

2016-07-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small-cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pathologically diagnosed non-small-cell lung cancer. Patients receiving immune checkpoints therapy. Inoperable advanced or recurrent non-small-cell lung cancer patients. Expected prognosis >3months. Aged 20 years or more. Informed consent was given.

Exclusion criteria

Exclusion criteria: Patients with current or history of autoimmune disease. Patients with interstitial lung disease. Patients receiving steroids or immune suppressive therapy. Inappropriate patients decided by attending physician.

Design outcomes

Primary

Measure	Time frame
Changes in proportion of immune cells in 2, 4, and 8 weeks after immune checkpoints therapy.	—

Countries

Japan

Contacts

Public ContactMasato Karayama

Hamamatsu University School of Medicine Department of Clinical Oncology

karayama@hama-med.ac.jp053-435-2419

Outcome results